VistaGen (NASDAQ:VTGN) Rating Restated
VistaGen (NASDAQ:VTGN) had its stock rating noted as Buy by analysts at Chardan Capital. Chardan Capital currently has a $22.0 price target on the $15.70 million market cap company or 1,748.74 % upside potential. This was disclosed to clients in a research report on Thursday morning.
NASDAQ:VTGN is currently trading 0.00% lower at $1.83 as of 4:09 AM New York time. VistaGen’s stock is 0% over the past 200 days. It has underperformed the S&P500, which has risen 6.00% over the same time period.
VistaGen (NASDAQ:VTGN) Profile
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).
VistaGen (NASDAQ:VTGN) closed at $1.83 yesterday. A total of shares of the company’s stock traded hands. This is down from average of 58,283 shares. VistaGen has a 52 week low of $1.74 and a 52 week high of $9. The company has a market cap of $15.70M and a P/E ratio of 0.
Get the latest VistaGen (NASDAQ:VTGN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Chardan Capital Analyst Reaffirmed $22.0 Price Target on VistaGen (NASDAQ:VTGN) stock, While Reiterating Buy Rating appeared first on Octafinance.